Clinical trials: Prostate Hyperplasia
Prostatic Hyperplasia, Benign Prostatic Hyperplasia
Rezum I Pilot Study for Benign Prostatic Hyperplasia
Evaluate the safety and efficacy of the Rezum System for the treatment of BPH
- Conditions
- Prostatic Hyperplasia, Benign Prostatic Hyperplasia, Adenoma, Prostatic, Prostatic Adenoma
- Trial name
- Rezum Pilot (NCT02943070)
- Testing
- Rezum System
- Where
- 3 sites in Czechia, Dominican Republic and 1 more
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Erectile Dysfunction, Benign Prostatic Hyperplasia
A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
Study LVHR is a Phase 3 study which will examine the efficacy and safety of tadalafil 2.5 and 5 mg once daily versus placebo for the treatment of erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia…
- Trial name
- COMORBID© (NCT00855582)
- Testing
- Tadalafil
- Where
- 52 sites in United States, Canada and 7 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia, Enlarged Prostate
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate…
- Trial name
- NCT01139762
- Testing
- Tadalafil, Finasteride
- Where
- 65 sites in United States, Argentina and 11 more
- Volunteers
- 696 people
- Sponsor
- Eli Lilly and Company
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign…
- Trial name
- NCT01460342
- Testing
- Tadalafil
- Where
- 17 sites in Japan, South Korea
- Volunteers
- 610 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
- Trial name
- NCT00224133
- Testing
- Silodosin
- Where
- 79 sites in United States
- Volunteers
- 661 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia (BPH)
To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
A real world study to evaluate the feasibility, preliminary safety and performance of Rezūm system in BPH treatment in China Rezūm RWS study
- Trial name
- NCT04823221
- Testing
- Rezūm System
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design, multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12 weeks in Asian men with signs and…
- Trial name
- NCT00861757
- Testing
- Tadalafil, Tamsulosin
- Where
- 6 sites in Japan, Taiwan
- Volunteers
- 612 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Prostatic Hyperplasia
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and…
- Trial name
- NCT01323998
- Testing
- 5ARI, AB
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such…
- Trial name
- NCT00848081
- Testing
- Tadalafil
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study of Tadalafil in Benign Prostatic Hyperplasia
The purpose of this study is to investigate the pharmacokinetics of tadalafil in Japanese and non-Japanese men with Benign Prostatic Hyperplasia (BPH). The safety of tadalafil will also be studied.
- Trial name
- NCT01183650
- Testing
- Tadalafil
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study in Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured…
- Trial name
- NCT01152190
- Testing
- Tadalafil
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
A bio-equivalence of 2 different capsule formulations in fasted subjects
- Trial name
- NCT02417831
- Testing
- tamsulosin capsules, tamsulosin HCl
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary…
- Trial name
- NCT00710749
- Testing
- Disposable device, Digital device, Clinic flow measurement
- Where
- 4 sites in United States, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wellspect HealthCare
Lower Urinary Tract Symptoms (LUTS)
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- DELUTS (NCT00947882)
- Testing
- Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 404 people
- Sponsor
- Ferring Pharmaceuticals